13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274403
Total reported value
$1.1B
$1.1B
9 檔
52.0%
In Q4 2025, ARCH Venture Management, LLC's U.S. equity holdings reached a combined market value of $1.1B, distributed across 9 disclosed stock positions.
ARCH Venture Management, LLC executed strategic sector rebalancing during Q4 2025, establishing 1 new positions while fully exiting 1 holdings and trimming 0 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MAZE | Maze Therapeutics Inc | Stock-Other | 26.19% | -6.98% | — | |
| 2 | BEAM | Beam Therapeutics Inc | Stock-Other | 19.31% | -1.82% | — | |
| 3 | RAPP | Rapport Therapeutics Inc | Stock-Other | 17.36% | -3.11% | — | |
| 4 | LYEL | Lyell Immunopharma Inc | Stock-Other | 13.03% | -5.48% | — | |
| 5 | VIR | Vir Biotechnology Inc | Stock-Other | 11.95% | -5.33% | — | |
| 6 | ERAS | Erasca Inc | Stock-Other | 6.31% | -5.14% | — | |
| 7 | GOSS | Gossamer Bio Inc | Stock-Other | 3.83% | -0.27% | — | |
| 8 | TXG | 10x Genomics Inc-class A | Stock-Other | 1.85% | +0.08% | — | |
| 9 | QTTB | Q32 Bio Inc | Stock-Other | 0.16% | -0.30% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MAZE | Maze Therapeutics Inc | +4.5% | — | Unchanged |
| 2 | LYEL | Lyell Immunopharma Inc | +3.9% | — | Unchanged |
| 3 | ERAS | Erasca Inc | +1.4% | — | Unchanged |
| 4 | QTTB | Q32 Bio Inc | 0% | — | Unchanged |
| 5 | GOSS | Gossamer Bio Inc | -0.5% | — | Unchanged |
| 6 | VIR | Vir Biotechnology Inc | -3% | — | Unchanged |
| 7 | BEAM | Beam Therapeutics Inc | -3.1% | — | Unchanged |
| 8 | RAPP | Rapport Therapeutics Inc | -5.1% | — | Unchanged |
| 9 | TXG | 10x Genomics Inc-class A | — | NEW | New buy |
| 10 | CERO | Cero Therapeutics Holdings I | — | EXIT | Sold out |
According to official SEC Form 13F filings, ARCH Venture Management, LLC reported a total U.S. public equity portfolio value of $1.1B across 9 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MAZE, BEAM, RAPP) accounted for 52.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
TXG
市值: $12.0M
Top Position Liquidated / Trimmed
CERO
前期市值: $114.0K
During Q4 2025, ARCH Venture Management, LLC's top holdings by market value included MAZE (26.2%)、BEAM (19.3%)、RAPP (17.4%). The largest single position, MAZE, represented 26.2% of total portfolio value.
In Q4 2025, ARCH Venture Management, LLC made 2 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.